Related references
Note: Only part of the references are listed.The economic burden of disease by industry: Differences in quality-adjusted life years and associated costs
Davina V. Tolbert et al.
AMERICAN JOURNAL OF INDUSTRIAL MEDICINE (2014)
Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences
Jesus Martin-Fernandez et al.
BMC HEALTH SERVICES RESEARCH (2014)
AN INSTRUMENT FOR MEASURING THE SOCIAL WILLINGNESS TO PAY FOR HEALTH STATE IMPROVEMENT
Jeff Richardson et al.
HEALTH ECONOMICS (2014)
Valuing QALYs at the end of life
Jose-Luis Pinto-Prades et al.
SOCIAL SCIENCE & MEDICINE (2014)
Estimating a WTP-based value of a QALY: The 'chained' approach
Angela Robinson et al.
SOCIAL SCIENCE & MEDICINE (2013)
Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?
Montarat Thavorncharoensap et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2013)
Disentangling WTP per QALY data: different analytical approaches, different answers
Dorte Gyrd-Hansen et al.
HEALTH ECONOMICS (2012)
A welfare economic approach to measure outcomes in stuttering: Comparing willingness to pay and quality adjusted life years
Duska M. Franic et al.
JOURNAL OF FLUENCY DISORDERS (2012)
Diminishing Willingness to Pay per Quality-Adjusted Life Year: Valuing Acute Foodborne Illness
Kevin Haninger et al.
RISK ANALYSIS (2011)
Cost-utility analysis: current methodological issues and future perspectives
Mark J. C. Nuijten et al.
FRONTIERS IN PHARMACOLOGY (2011)
Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE
Rachel Baker et al.
HEALTH ECONOMICS POLICY AND LAW (2011)
INTERNATIONAL SURVEY ON WILLINGNESS-TO-PAY (WTP) FOR ONE ADDITIONAL QALY GAINED: WHAT IS THE THRESHOLD OF COST EFFECTIVENESS?
Takeru Shiroiwa et al.
HEALTH ECONOMICS (2010)
WILLINGNESS TO PAY PER QUALITY ADJUSTED LIFE-YEAR: IS ONE THRESHOLD APPLICABLE FOR ALL DECISION-MAKING?
F. L. Zhao et al.
VALUE IN HEALTH (2010)
Willingness to Pay for a Quality-Adjusted Life-Year: The Individual Perspective
Ana Bobinac et al.
VALUE IN HEALTH (2010)
Quantification of the Potential Impact of Cost-effectiveness Thresholds on Dutch Drug Expenditures Using Retrospective Analysis
Cornelis Boersma et al.
VALUE IN HEALTH (2010)
How to do (or not to do) Designing a discrete choice experiment for application in a low-income country
Lindsay J. Mangham et al.
HEALTH POLICY AND PLANNING (2009)
Trying to estimate a monetary value for the QALY
Jose Luis Pinto-Prades et al.
JOURNAL OF HEALTH ECONOMICS (2009)
Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster
Tracy A. Lieu et al.
PHARMACOECONOMICS (2009)
Cost Effectiveness in Low- and Middle-Income Countries A Review of the Debates Surrounding Decision Rules
Samuel D. Shillcutt et al.
PHARMACOECONOMICS (2009)
How much are Americans willing to pay for a quality-adjusted life year?
Milton C. Weinstein
MEDICAL CARE (2008)
The NICE cost-effectiveness threshold - What it is and what that means
Christopher McCabe et al.
PHARMACOECONOMICS (2008)
Conducting discrete choice experiments to inform Healthcare decision making
Emily Lancsar et al.
PHARMACOECONOMICS (2008)
Willingness to pay for a QALY: past, present and future
Helen Mason et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2008)
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Scott D Grosse
Expert Review of Pharmacoeconomics & Outcomes Research (2008)
At what hip fracture risk is it cost-effective to treat?: International intervention thresholds for the treatment of osteoporosis
F. Borgstroem et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Economic evaluation of health-care programmes: Is CEA better than CBA?
Amiram Gafni
ENVIRONMENTAL & RESOURCE ECONOMICS (2006)
Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis
MM Byrne et al.
MEDICAL DECISION MAKING (2005)
Willingness to pay for a quality-adjusted life year: Implications for societal health care resource allocation
JT King et al.
MEDICAL DECISION MAKING (2005)
Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: results of a survey
DM Franic et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2005)
Use of cost-effectiveness analysis in health-care resource allocation decision-making:: How are cost-effectiveness thresholds expected to emerge?
HG Eichler et al.
VALUE IN HEALTH (2004)
QALYs versus WTP
JK Hammitt
RISK ANALYSIS (2002)
Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis?
P Dolan et al.
JOURNAL OF HEALTH ECONOMICS (2002)
Cost effectiveness analysis and the consistency of decision making - Evidence from pharmaceutical reimbursement in Australia (1991 to 1996)
B George et al.
PHARMACOECONOMICS (2001)
Willingness to pay for a quality-adjusted life year: In search of a standard
RA Hirth et al.
MEDICAL DECISION MAKING (2000)
Are pharmaceuticals cost-effective? A review of the evidence
PJ Neumann et al.
HEALTH AFFAIRS (2000)